Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Revance Therapeutics stock | 26.7

Own Revance Therapeutics stock in just a few minutes.

Posted

Fact checked

Revance Therapeutics, Inc is a biotechnology business based in the US. Revance Therapeutics shares (RVNC) are listed on the NASDAQ and all prices are listed in US Dollars. Revance Therapeutics employs 193 staff and has a trailing 12-month revenue of around USD$4.3 million.

How to buy shares in Revance Therapeutics

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Revance Therapeutics. Find the stock by name or ticker symbol: RVNC. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Revance Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$26.7, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Revance Therapeutics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Revance Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Revance Therapeutics share price

Use our graph to track the performance of RVNC stocks over time.

Revance Therapeutics shares at a glance

Information last updated 2020-11-25.
Latest market close USD$26.7
52-week range USD$11.78 - USD$33.64
50-day moving average USD$25.9013
200-day moving average USD$25.0495
Wall St. target price USD$35.8
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-3.712

Buy Revance Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Vanguard
$0
Stocks, Mutual funds, ETFs, Forex
$1
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Revance Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Revance Therapeutics price performance over time

Historical closes compared with the close of $26.7 from 2020-11-16

1 week (2020-11-20) N/A
1 month (2020-10-28) N/A
3 months (2020-08-28) N/A
6 months (2020-05-28) N/A
1 year (2019-11-27) N/A
2 years (2018-11-27) N/A
3 years (2017-11-27) N/A
5 years (2015-11-27) N/A

Revance Therapeutics financials

Revenue TTM USD$4.3 million
Gross profit TTM USD$413,000
Return on assets TTM -30.35%
Return on equity TTM -95.05%
Profit margin 0%
Book value $5.599
Market capitalisation USD$1.6 billion

TTM: trailing 12 months

Shorting Revance Therapeutics shares

There are currently 4.1 million Revance Therapeutics shares held short by investors – that's known as Revance Therapeutics's "short interest". This figure is 1.5% up from 4.0 million last month.

There are a few different ways that this level of interest in shorting Revance Therapeutics shares can be evaluated.

Revance Therapeutics's "short interest ratio" (SIR)

Revance Therapeutics's "short interest ratio" (SIR) is the quantity of Revance Therapeutics shares currently shorted divided by the average quantity of Revance Therapeutics shares traded daily (recently around 607210.40118871). Revance Therapeutics's SIR currently stands at 6.73. In other words for every 100,000 Revance Therapeutics shares traded daily on the market, roughly 6730 shares are currently held short.

However Revance Therapeutics's short interest can also be evaluated against the total number of Revance Therapeutics shares, or, against the total number of tradable Revance Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Revance Therapeutics's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Revance Therapeutics shares in existence, roughly 60 shares are currently held short) or 0.0691% of the tradable shares (for every 100,000 tradable Revance Therapeutics shares, roughly 69 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Revance Therapeutics.

Find out more about how you can short Revance Therapeutics stock.

Revance Therapeutics share dividends

We're not expecting Revance Therapeutics to pay a dividend over the next 12 months.

Revance Therapeutics share price volatility

Over the last 12 months, Revance Therapeutics's shares have ranged in value from as little as $11.78 up to $33.64. A popular way to gauge a stock's volatility is its "beta".

RVNC.US volatility(beta: 1.61)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Revance Therapeutics's is 1.6133. This would suggest that Revance Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Revance Therapeutics overview

Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection (DAXI) which competed phase 3 clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; in phase 2 clinical trials to treat adult upper limb spasticity and plantar fasciitis, and in pre-clinical trials to treat chronic migraine. It is also developing DAXI for forehead lines, lateral canthal lines, and upper facial lines that is in phase 2 clinical trials; DaxibotulinumtoxinA Topical for therapeutic and aesthetic applications; and OnabotulinumtoxinA, a biosimilar to BOTOX. The company has a collaboration agreement with Mylan Ireland Limited for the development, manufacture, and commercialization of a biosimilar to BOTOX; and collaboration and license agreement with Mylan N.V. for the development and regulatory approval of a biosimilar to BOTOX. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was founded in 1999 and is headquartered in Newark, California.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site